Mevidalen
Small molecule
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
Development in Alzheimer's Disease stopped (2026-10-30) as a strategic decision by the sponsor. Development continues in another indication. Source
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06538116 NCT06538116 · Alzheimer Disease Study of the molecule, not a specific product The trial randomized 304 participants to two mevidalen dose groups or placebo and used double blinding of participants and investigators. Its primary clinical cognitive-and-functional endpoint was specified, but results and statistical comparisons are not yet available. Registry: NCT06538116 | 2 | Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) (Baseline, Week 24) 2026-05-01 | Results not posted; external-source review pending | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.
Phase 2 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.